{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:07:40Z","timestamp":1775646460366,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Minister of Instruction, University and Research","award":["20109PLMH2"],"award-info":[{"award-number":["20109PLMH2"]}]},{"name":"\u201cBeneficentia Stiftung\u201d"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijpharm.2017.02.020","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T10:30:38Z","timestamp":1486636238000},"page":"377-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer"],"prefix":"10.1016","volume":"525","author":[{"given":"Sabrina","family":"Bochicchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Dapas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Ciacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefaan","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Pottie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Angela","family":"Barba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2017.02.020_bib0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biochi.2008.10.015","article-title":"Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels","volume":"91","author":"Baiz","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-2836(64)80115-7","article-title":"Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope","volume":"8","author":"Bangham","year":"1964","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0015","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1039\/c3sm52879k","article-title":"Ultrasonic energy in liposome production: process modelling and size calculation","volume":"10","author":"Barba","year":"2014","journal-title":"Soft Matter"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2174\/1389200216666150812142557","article-title":"Novel lipid and polymeric materials as delivery systems for nucleic acid based drugs","volume":"16","author":"Barba","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0025","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2174\/1389200216666150206124913","article-title":"Liposomes as siRNA delivery vectors","volume":"15","author":"Bochicchio","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lwt.2016.01.025","article-title":"Vitamin delivery: carriers based on nanoliposomes produced via ultrasonic irradiation","volume":"69","author":"Bochicchio","year":"2016","journal-title":"LWT-Food Sci. Technol."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0035","first-page":"203","article-title":"New preparative approaches for micro and nano drug delivery carriers","volume":"14","author":"Bochicchio","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nano.2015.08.006","article-title":"Nanomedicine applied to translational oncology: a future perspective on cancer treatment","volume":"12","author":"Bregoli","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0050","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/00365521.2015.1014407","article-title":"The epidemiology of inflammatory bowel disease","volume":"50","author":"Burisch","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0005-2736(01)00290-5","article-title":"Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties","volume":"1512","author":"Campbell","year":"2001","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2119\/molmed.2009.00030","article-title":"Role of E2F1\u2013cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs","volume":"15","author":"Dapas","year":"2009","journal-title":"Mol. Med."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1359-6446(04)03353-7","article-title":"Discovery and development of biomarkers of neurological disease","volume":"10","author":"Dunckley","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cytogfr.2016.02.001","article-title":"E2F1 transcription factor and its impact on growth factor and cytokine signaling","volume":"31","author":"Ertosun","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bbrc.2015.06.103","article-title":"E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2","volume":"464","author":"Fang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0080","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.dld.2011.07.007","article-title":"Effects of E2F1\u2013cyclin E1\u2013E2 circuit down regulation in hepatocellular carcinoma cells","volume":"43","author":"Farra","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0085","first-page":"272","article-title":"The role of the transcription factor E2F1 in hepatocellular carcinoma","volume":"14","author":"Farra","year":"2017","journal-title":"Curr Drug Deliv."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0090","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.gastro.2009.12.037","article-title":"AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Farraye","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijpharm.2016.06.026","article-title":"Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes","volume":"510","author":"Golkar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2016.05.027","article-title":"Bioconjugated gold nanoparticles enhance cellular uptake: a proof of concept study for siRNA delivery in prostate cancer cells","volume":"509","author":"Guo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2013.11.041","article-title":"Gene therapy and DNA delivery systems","volume":"459","author":"Ibraheem","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/humu.22021","article-title":"Differential MicroRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer","volume":"33","author":"Kanaan","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0115","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2016.05.047","article-title":"Anti-Tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors","volume":"509","author":"Kibria","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijpharm.2009.08.036","article-title":"Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat","volume":"383","author":"Kigasawa","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpharm.2010.03.047","article-title":"Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid","volume":"392","author":"Kim","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0130","article-title":"Colorectal cancer","volume":"1","author":"Kuipers","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1442-2050.2005.00463.x","article-title":"Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma","volume":"18","author":"Mega","year":"2005","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0140","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1053\/j.gastro.2007.09.001","article-title":"Diagnostics of inflammatory bowel disease","volume":"133","author":"Nikolaus","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0145","first-page":"89","article-title":"Quantification strategies in real-time PCR","volume":"1","author":"Pfaffl","year":"2004","journal-title":"AZ Quant. PCR"},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0150","first-page":"246","article-title":"Cyclin D1 Gene Silencing by siRNA in ex vivo human tissue cultures","volume":"14","author":"Piazza","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0155","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijpharm.2014.11.012","article-title":"Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: s potential candidate for overcoming multi-drug resistance","volume":"477","author":"Ran","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.gt.3302356","article-title":"siRNA therapeutics: big potential from small RNAs","volume":"12","author":"Ryther","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0175","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijpharm.2016.06.127","article-title":"Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles","volume":"510","author":"Wei","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.02.020_bib0180","doi-asserted-by":"crossref","first-page":"9286","DOI":"10.1158\/0008-5472.CAN-07-2238","article-title":"Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation","volume":"67","author":"Ying","year":"2007","journal-title":"Cancer Res."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317301011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317301011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T12:27:04Z","timestamp":1536064024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517317301011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0378517317301011"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.02.020","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}